# Week of January 31 – February 4, 2022

## OUHSC DEPARTMENT OF MEDICINE CONFERENCE SCHEDULE

**NOTE: All CME conferences will be designated by an \* by the name of the conference.**

|  |  |
| --- | --- |
| **Monday, January 31, 2022** |  |

 12:15 – 1:00 PM Medicine House Staff Conference: “Case Report,” Brian Scott, MD, Medicine Resident. AAT Conf Rm A&B

 12:15 – 1:15 PM Pulmonary and Critical Care Conference: “Research Conference,” Ahel El Haj Chehade, MD, Pulmonary Fellow and Chirin Orabi, MD, Pulmonary Fellow. AAT 8200

|  |  |
| --- | --- |
| **Tuesday, February 1, 2022** |  |

 7:15 – 8:00 AM Cardiology Cath Conference: Case Presentation. AAT 5200 or Zoom Meeting

 8:00 – 9:00 AM Endocrinology Grand Rounds/Research Conference: “Case Conference,” Peter Lambert, MD, Endocrinology Fellow. HHDC 2923

 Learning Objectives: Upon completion of this session, participants will improve their competence and performance by being able to: Recognize challenging patient cases encountered in the inpatient and/or outpatient setting. Review different treatment options available for the management of these cases.

 12:15 – 1:15 PM **\***Medicine Grand Rounds: “The Spreading Cloud of Silicosis: what we inhale matters,” Jad Kebbe, MD, Assistant Professor, Department of Medicine/Pulmonary, Director of Interstitial Lung Disease Program. Available by Zoom Meeting ID: 235 085 3917 Password: 64006434 <https://zoom.us/j/2350853917?pwd=VjhidnpNVmdmUm8yL2c4NHFVeWRTZz09> or join us by phone, 1-602-753-0140 (1.00 *AMA PRA Category 1 Credit™)*

Professional Practice Gap: Gap 1: Silica is a commonly present inhaled inorganic antigen worldwide. It remains often unrecognized, yet is linked to irreversible and deadly lung disease. Gap 2: Groups of people from underserved populations in Oklahoma are subject to high exposure and resultant elevated risk of developing silicosis.

Learning Objectives: Upon completion of this session, participants will improve their competence and performance by being able to: Identify worldwide risks associated with exposure to silica. Categorize the phenotypes of related lung diseases. Integrate screening strategies into daily practice. Formulate preventative and therapeutic strategies.

 Speaker Disclosure: Dr. Kebbe has no relevant financial relationships or affiliations with commercial interests to disclose.

|  |  |
| --- | --- |
| **Wednesday, February 2, 2022** |  |

 7:00 – 8:00 AM Vascular Conference: AAT 9200

 7:15 – 8:00 AM Cardiology Program Director Meeting: AAT 5200

 8:15 – 9:00 AM ID Case Conference: AAT Conf Rm C

 12:15 – 1:00 PM Medicine House Staff Conference: Case Report. AAT Conf Rm A&B

 12:15 – 1:15 PM Pulmonary and Critical Care Conference: “Cardiac Ultrasound and Volume Assessment,” Houssein Youness, MD, Associate Professor, Department of Medicine/Pulmonary. AAT 8200

 1:30 – 2:30 PM Renal Grand Rounds: Case Consultation: AAT 5328

 1:30 – 3:30 PM Rheumatology Clinical Conference: “Ortho (Shoulder or Knee),” Sheila Algan, MD, Associate Professor, Department of Orthopedic Surgery and Rehabilitation, Sports Medicine and Arthroscopic Surgery. AAT Conf Rm, 1st Fl, Rm B

 3:00 – 4:00 PM GI Conference: SOCI Conference November & December/Interdisciplinary Committee Reports,” Blair Kirkpatrick, MD, Digestive Diseases Fellow, Karl Mareth, MD, Digestive Diseases Fellow, and Evgeny Idrisov, MD, Digestive Diseases Fellow. AAT Conf Rm, 1st Fl, Rm C

 4:00 – 5:00 PM GI Advanced Endoscopy Conference: AAT Conf Rm, 1st Fl, Rm C

**Department of Medicine Conference Schedule February31 – February 4, 2022**

|  |  |
| --- | --- |
| **Thursday, February 3, 2022** |  |

 7:15 – 8:00 AM Cardiovascular Grand Rounds: “Antiplatelet Agents: A Review for the CV Team for Safe and Effective Use,” Razan Elsayed, MD, Cardiovascular Fellow. Zoom Meeting

 12:15 – 1:00 PM Medicine House Staff Conference: AAT Conf Rm A&B

 12:15 – 1:15 PM Pulmonary and Critical Care Conference: Mortality and Morbidity. AAT 8200

|  |  |
| --- | --- |
| **Friday, February 4, 2022** |  |

 7:15 – 8:00 AM Echocardiography Conference: AAT 5200

 8:00 – 9:00 AM Hematology/Oncology Grand Rounds Conference: “Breast Cancer with PIK3 Inhibitor,” Aditya Bardia, MD, Assistant Professor, Medicine, Harvard Medical School, Attending Physician, Medical Oncology, Massachusetts General Hospital. SCC 6039/Zoom Meeting

 12:15 – 1:00 PM Medicine House Staff Conference: Chief Session. AAT Conf Rm A&B

 12:15 – 1:15 PM Pulmonary and Critical Care Conference: Instructive Case Conference. AAT 8200

 1:30 – 2:30 PM Combined Thoracic-Oncology Clinical Care Conference: VAMC 5F-121

For accommodations on the basis of disability, call 405-271-6655 x1.

FUTURE EVENTS

### Check out the Internet listing of grand rounds and seminars at: <http://www.ouhsc.edu/insidehsc/>

To place name on mailing list or provide input for future schedules, contact Ms. Brenda Wilkerson, Department of Medicine. Schedules are typically e-mailed on Thursday of the week prior to the week of listed activities. If you wish to receive this via e-mail, you may use the Internet to request it. Address: Brenda-Wilkerson@ouhsc.edu

**Accreditation Statement:** The University Of Oklahoma College Of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Mitigation Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

**Acknowledgement of Commercial and In-Kind Support:** Commercial support is financial, or in-kind, contributions given by an ineligible company, which is used to pay all or part of the costs of a CME activity.  An ineligible company is any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity received no commercial or in-kind support.

**University Equal Opportunity / Non-Discrimination Statement:** The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides.

To file a grievance related to the non-discrimination policy, report sexual misconduct, and/or file a formal complaint of sexual misconduct, please utilize the reporting form at [link.ou.edu/reportingform](file:///%5C%5Cdch-comd1%5Cdo%5Cocpd%5C22D%20RSS%202021-2022%5C22D%20To%20Do%5Clink.ou.edu%5Creportingform).

Inquiries regarding non-discrimination policies may be directed to the Office(s) of Institutional Equity as may be applicable – Norman campus: (405) 325-3546/3549, Health Sciences Center: (405) 271-2110, or OU-Tulsa Title IX Office: (918) 660-3107. Additionally, individuals may visit [www.ou.edu/eoo](http://www.ou.edu/eoo).

**Accommodations Statement:** For accommodations, please contact the Dept. of Medicine at 405-271-6651 ext. 1.

**Policy on Planner and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Disclosure & Mitigation Report**

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities.  We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity’s disclosure and mitigation information.

|  |  | **Nature of the Financial Relationship** |
| --- | --- | --- |
| **Role**  | **First Name** | **Last Name**  | **Commercial Interest** | **What was received?** | **For what role?** |
| Planning Committee/ Presenter | Adam S. | Asch, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee/ Presenter | Mary Zoe | Baker, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Course Director/ Moderator | Michael S.  | Bronze, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee/ Presenter | Brent R. | Brown, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee/ Presenter/ Moderator | Benjamin D. | Cowley, Jr, MD | Otsuka | Consultant Fee | Monitoring Committee, Trial |
| **Planner:** Dr. Cowley has recused himself from planning content in the conflicted area. **Moderator:** Dr. Cowley will limit his role to the introduction of presenters, fielding questions, and moderating the flow of discussion between participants and presenters. **Presenter:** The conflict was resolved by Dr. Cowley agreeing to only present peer-reviewed, published data and recommendations that have been previewed by the OU CPD office. |
| Planning Committee / Presenter / Moderator | Douglas A. | Drevets, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee | Courtney W. | Houchen, MD | COARE Biotechnology | Grants/Research | Co-Founder |
| **Planner:** Dr. Houchen has recused himself from planning content in the conflicted area. |
| Planning Committee / Presenter | Mary Beth | Humphrey, MD, PhD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee | Rhett L. | Jackson, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee | Lee A. | Jennings, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Presenter | Jad | Kebbe, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Committee / Presenter | Dwight W. | Reynolds, MD | Medtronic, Inc | Honorarium | Speaker, Advisory Board |
| Medtronic, Inc | Research Funding | Primary Investigator |
| **Planner:** Dr. Reynolds has recused himself from planning content in the conflicted areas. **Presenter:** The conflict was resolved by Dr. Reynolds agreeing that the presentation(s) will not include discussion of any products or services from the commercial interests. |
| Course Contact | Brenda E. | Wilkerson | I have no financial relationships or affiliations with ineligible companies to disclose. |